Stifel analyst Thomas Stephan lowered the firm’s price target on Alcon (ALC) to $85 from $90 and keeps a Buy rating on the shares. The firm, whose sales bridge analysis of core sales and new product sales suggests that second half upside remains unclear despite the recent guidance reduction, contends that “numbers still may not be fully reset,” but still argues that the recent pullback in shares is “compelling.” The firm believes the Street’s 2026 EPS estimate needs to come down before shares can start to work in the near-term, but adds that valuation limits significant downside risk in the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Staar Surgical sees FY26 revenue $340M, consensus $319.33M
- Staar Surgical reports expiration of window shop period under Alcon merger pact
- Yunqi Capital intends to vote against STAAR Surgical sale to Alcon
- Alcon management to meet with Mizuho
- Staar Surgical issues letter to stockholders regarding Alcon merger